The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
== Epidemiology == The prevalence of GDM was 14.7%, 9.9%, and 14.4% in low-income countries (LIC), middle-income countries (MIC), and high-income countries (HIC) in 2021 by the International Association of Diabetes in Pregnancy Study Group's criteria. By 2021, the Global prevalence of hyperglycemia in pregnancy (HIP) as per the IDF atlas will be 21.1 million people, accounting for 16.7% of births to women aged 20-49. These individuals may experience some form of hyperglycemia during pregnancy; 80.3% of these were due to GDM.
== Function == This gene encodes a multifunctional protein. It has two enzymatically active domains with catalytic activities - peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL). These catalytic domains work sequentially to catalyze neuroendocrine peptides to active alpha-amidated products. The reaction pathway catalyzed by PAM is accessed via quantum tunneling and substrate preorganization. Multiple alternatively spliced transcript variants encoding different isoforms have been described for this gene, but some of their full-length sequences are not yet known. The PHM subunit effects hydroxylation of a C-terminal glycine residue:
The ability of an ice road to safely support the weight of a vehicle, or any other loads applied onto it, referred to as bearing capacity, is the primary concern when designing, building and using that structure. Generally speaking, a vertically loaded ice cover will react in two ways: 1) it will sink, and 2) it will bend in flexure. In order to meet the ice bearing criteria, the top surface should not sink below the water line and the applied flexural stress should not exceed the ice's flexural strength. Three loading regimes have to be considered: a) maximum weight for standard usage or for parking during a short duration; b) a load that remains stationary during an extensive time period; and c) dynamic loading of the ice cover, from a traveling vehicle.
== Early life and education == Bibudhendra Sarkar was born on August 2, 1935, in Kushtia, Bengal, British India (now Bangladesh). His father, Surendra Nath Sarkar, was a lawyer, and his mother, Sucheta Sarkar (née Chaki), a homemaker, died when he was one year old. He completed his kindergarten and primary education at Kushtia Mission School, a Catholic institution. Following the Partition of India in 1947, Sarkar's family relocated to Calcutta after losing their possessions. He attended City College School and later City College, Kolkata, earning his Matriculation and Intermediate Science certifications from the University of Calcutta. He pursued higher education at Banaras Hindu University in Uttar Pradesh, specializing in the chemistry of natural products and earning Bachelor of Pharmacy (B.Pharm) and Master of Pharmacy (M.Pharm) degrees. During his undergraduate studies, Sarkar worked as a summer researcher at the Central Drug Research Institute in Lucknow, under the mentorship of Manojit Mohan Dhar, who encouraged him to pursue graduate studies abroad. He subsequently moved to the United States, completing a PhD in biochemistry at the University of Southern California in 1964 under the supervision of Paul Saltman. At USC, his work was influenced by chemists Sydney Benson (chemical kinetics), Arthur Adamson (physical chemistry), and Bo Malmström (metal-activated enzyme chemistry).
Sources: en.wikipedia.org
== Diagnosis == Zinc concentrations are typically quantified using instrumental methods such as atomic absorption, emission, or mass spectroscopies; X-ray fluorescence; electro-analytical techniques (e.g., stripping voltammetry); or neutron activation analysis. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) is used for zinc determinations in blood and tissue samples (NIOSH Method 8005) and in urine (NIOSH Method 8310). Detection limits in blood and tissue are 1 μg/100 g and 0.2 μg/g, respectively, with recoveries of 100% (NIOSH 1994). Sample preparation involves acid digestion using concentrated acids. Detection of zinc in urine samples requires extraction of the metals with a polydithiocarbamate resin prior to digestion and analysis (NIOSH 1984). Detection limits in urine are 0.1 μg/sample.
Differential stresses arising from inhomogeneous densification have also been shown to result in the propagation of internal cracks, thus becoming the strength-controlling flaws. Inert gas evaporation and inert gas deposition are free many of these defects due to the distillation (cf. purification) nature of the process and having enough time to form single crystal particles, however even their non-aggreated deposits have lognormal size distribution, which is typical with nanoparticles. The reason why modern gas evaporation techniques can produce a relatively narrow size distribution is that aggregation can be avoided. However, even in this case, random residence times in the growth zone, due to the combination of drift and diffusion, result in a size distribution appearing lognormal. It would, therefore, appear desirable to process a material in such a way that it is physically uniform with regard to the distribution of components and porosity, rather than using particle size distributions that will maximize the green density. The containment of a uniformly dispersed assembly of strongly interacting particles in suspension requires total control over interparticle forces. Monodisperse nanoparticles and colloids provide this potential.
Thus, the PZC refers to the absence of any type of surface charge, while the IEP refers to a state of neutral net surface charge. The difference between the two, therefore, is the quantity of charged sites at the point of net zero charge. Jolivet uses the intrinsic surface equilibrium constants, pK− and pK+ to define the two conditions in terms of the relative number of charged sites:
=== Transit === On December 16, 2025, Pritzker signed into law the Illinois People Over Parking Act, which disburses $1.5 billion to address post-COVID-19 budget shortfalls for Chicagoland-area transit authorities to avoid service cuts; reduces the farebox revenue share of total funding from 50% to 25%, since post-pandemic reductions in ridership made these expectations unreasonable; and disburses $169 million to downstate transit agencies to cover similar budget shortfalls. It prevents transit agencies from transferring funding for operations to capital investment. Local jurisdictions are prohibited from establishing minimum parking requirements within half a mile of transit rail stations and bus hubs or one-eighth mile of corridors with combined bus route frequency of 15 minutes or less during peak periods under this legislation. The bill also reorganizes the Regional Transportation Authority into the Northern Illinois Transit Authority, which is intended to centralize decision-making power away from individual counties and synchronize operations of the Chicago Transit Authority, Metra, and Pace. The NITA board is to have 20 members, five assigned by the mayor of Chicago, the Cook County President, and the governor, and five by the five collar counties, where 15 votes are needed to affirm board actions, or 12 if two affirmative votes from each of the four appointing authorities are cast; and a majority of CTA, Metra, and Pace board members are to be simultaneously staffed by NITA board members.
The Liberal Party lacked a unified ideological base in 1906. It contained numerous contradictory and hostile factions, such as imperialists and supporters of the Boers; near-socialists and laissez-faire classical liberals; suffragettes and opponents of women's suffrage; antiwar elements and supporters of the military alliance with France. Nonconformists – Protestants outside the Anglican fold – were a powerful element, dedicated to opposing the established church in terms of education and taxation. However, the non-conformists were losing support amid society at large and played a lesser role in party affairs after 1900. The party, furthermore, also included Irish Catholics, and secularists from the labour movement. Many Conservatives (including Winston Churchill) had recently protested against high tariff moves by the Conservatives by switching to the anti-tariff Liberal camp, but it was unclear how many old Conservative traits they brought along, especially on military and naval issues. The middle-class business, professional and intellectual communities were generally strongholds, although some old aristocratic families played important roles as well. The working-class element was moving rapidly toward the newly emerging Labour Party. One uniting element was widespread agreement on the use of politics and Parliament as a device to upgrade and improve society and to reform politics. All Liberals were outraged when Conservatives used their majority in the House of Lords to block reform legislation.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.